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Abstract
Background: Increasing the biological effective dose (BED) of radiotherapy for non-small cell lung cancer (NSCLC)
can increase local control rates and improve overall survival. Compared with conventional fractionated radiotherapy,
accelerated hypofractionated radiotherapy can yield higher BED, shorten the total treatment time, and theoretically
obtain better efficacy. However, currently, there is no optimal hypofractionated radiotherapy regimen. Based on
phase I trial results, we performed this phase II trial to further evaluate the safety and preliminary efficacy of
accelerated hypofractionated three-dimensional conformal radiation therapy(3-DCRT) combined with concurrent
chemotherapy for patients with unresectable stage III NSCLC.
Methods: Patients with previously untreated unresectable stage III NSCLC received 3-DCRT with a total dose of
69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, completed within 4.6 weeks. At the same
time, platinum doublet chemotherapy was applied.
Results: After 12 patients were enrolled in the group, the trial was terminated early. There were five cases of grade
III radiation esophagitis, of which four cases completed the radiation doses of 51 Gy, 51 Gy, 54 Gy, and 66 Gy, and
one case had 16 days of radiation interruption. The incidence of grade III acute esophagitis in patients receiving an
irradiation dose per fraction ≥2.7 Gy on the esophagus was 83.3 % (5/6). The incidence of symptomatic grade III
radiation pneumonitis among the seven patients who completed 69 Gy according to the plan was 28.6 % (2/7).
The median local control (LC) and overall survival (OS) were not achieved; the 1-year LC rate was 59.3 %, and the 1-year
OS rate was 78.6 %.
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Conclusion: For unresectable stage III NSCLC, the accelerated hypofractionated radiotherapy with a total dose of 69 Gy
(3 Gy/f) combined with concurrent chemotherapy might result in severe radiation esophagitis and pneumonitis to
severely affect the completion of the radiotherapy. Therefore, we considered that this regimen was infeasible. During
the hypofractionated radiotherapy with concurrent chemotherapy, the irradiation dose per fraction to esophagus
should be lower than 2.7 Gy. Further studies should be performed using esophageal tolerance as a metric in dose
escalation protocols.
Trial registration: NCT02720614, the date of registration: March 23, 2016.
Keywords: Non-small cell lung cancer, Accelerated hypofractionated radiotherapy, Three-dimensional conformal
radiation therapy, Concurrent radiochemotherapy, Maximum tolerated dose
Background
According to the 2008 global cancer statistics, the mor-
bidity and mortality of lung cancer ranks first worldwide
[1]. China also faces a similar situation. According to the
2010 data released by the National Cancer Control Of-
fice of the National Cancer Center, the new cases of lung
cancer every year totaled approximately 600,000, and the
cases of death number approximately 490,000 [2]. For
unresectable locally advanced non-small cell lung cancer
(NSCLC), concurrent radiochemotherapy is the standard
treatment [3, 4]. The classical concurrent radiochemo-
therapy program uses conventional fractionated radi-
ation with a total dose of 60–66 Gy; however, the local
recurrence rate is still as high as 30 % [4]. Studies have
suggested that increasing the tumor radiation dose could
increase the local control, thus improving survival [5, 6].
However, the RTOG06-17 study using the conventional
fractionated regimen showed that, compared with the
60-Gy group, the survival was not increased in the 74-Gy
high-dose group [7]. Although the exact reasons were not
clear, the very long treatment time (7.4 weeks) in the
high-dose group might be one of the reasons [3].
Studies in head and neck squamous cell carcinoma have
shown that tumor cells start to accelerate repopulation
after 4 weeks of radiotherapy; at this time, the doubling
time of tumor cells shortened from 60 days without inter-
ference to 4 days. To eliminate this re-proliferation, an
extra 0.6-Gy dose was required each day for compensation
[8]. This result also partially explained the possible reasons
behind the poor effect of conventional fractionated radio-
therapy. For NSCLC radiotherapy, after 4 weeks, when the
treatment time was increased by 1 day, a 0.45-Gy radi-
ation dose was lost. Therefore, extension of the total treat-
ment time might be a key reason causing the failure of
local control [9]. The continuous, hyperfractionated, ac-
celerated radiotherapy (CHART) program continued giv-
ing hyperfractionated radiation for 12 days; although the
total dose was only 54 Gy, the absolute value of the 2-year
survival increases by 9 % compared with the conven-
tional fractionation of 60 Gy (2 Gy/fraction) (29 % vs
20 %, respectively) [10]. Hypofractionated radiotherapy
has a dosimetric advantage; it shortens the treatment time,
increases the biological effective dose (BED), and can po-
tentially reduce the effect of accelerated repopulation on
local failure [6, 11]. Compared with hyperfractionated ra-
diation, hypofractionated radiotherapy has the advantages
of convenience, economy, and easy implementation; thus,
it has increasingly more clinical applications [12–29].
It has been confirmed that combined radiochemother-
apy is better than radiotherapy alone [30], conventional
fractionated radiotherapy with concurrent chemotherapy
is better than sequential radiotherapy and chemotherapy,
and the overall survival (OS) shows benefits with a 5.7 %
3-year OS and a 4.5 % 5-year OS [4]. Similarly, hypofrac-
tionated radiotherapy combined with concurrent chemo-
therapy can also theoretically further increase the efficacy.
Experimental research has shown that hypofractionated
radiotherapy with concurrent chemotherapy could in-
crease the efficacy [31]. However, due to the concern
about the aggressive toxicity of hypofractionated radio-
therapy with concurrent chemotherapy, this type of clin-
ical research is relatively rare. The applied fractionated
dose and chemotherapy regimens have larger differences,
and the optimal program of hypofractionated radiotherapy
with concurrent chemotherapy has not been confirmed.
We previously conducted a phase I study of hypofrac-
tionated radiotherapy (3 Gy/fraction) with concurrent
chemotherapy and considered that NSCLC could tolerate
the high 69-Gy dose [32]. Base on this finding, we per-
formed the current phase II study to further evaluate the
safety and preliminary efficacy of 69-Gy/23-fraction (3 Gy/
fraction) hypofractionated radiotherapy with concurrent
radiochemotherapy. Only 12 cases were enrolled in this
study. Because of the strong esophagus and lung toxicity,




Patients with previously untreated unresectable stage
IIIA or stage IIIB NSCLC (as defined by the 2009 staging
standards of the International Union Against Cancer
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(UICC)) were recruited, who were confirmed pathologic-
ally or cytologically. The age range was between 18 and
75 years, the Karnofsky performance status (KPS) score
was ≥70, and the expected survival time was ≥3 months.
The laboratory examination results showed a neutrophil
count ≥2.0 × 109, a hemoglobin level ≥100 g/L, a platelet
count ≥100 × 109, and the values of serum creatinine, ala-
nine aminotransferase, aspartate aminotransferase, and
total bilirubin were lower than the upper limit of the nor-
mal values. The patients did not show abnormal electro-
cardiogram (ECG) results. Additionally, they did not have
other combined diseases that required hospitalization.
Exclusion criteria
Patients who were pregnant, breastfeeding, had another
malignant tumor history (with the exception of patients
with cervical carcinoma in situ and non-malignant mel-
anoma skin cancer that had been clinically cured for at
least 5 years), could not receive concurrent chemother-
apy due to medical reasons, and had superior vena cava
syndrome and severe lung diseases that affected lung
function were excluded.
This clinical trial was approved by the Ethics Committee
of the North China Petroleum Bureau General Hospital of
Hebei Medical University. This trial was performed in ac-
cordance with the principles of human clinical trials and
the Helsinki Declaration (1975 edition and 2000 revised
edition). All of the patients signed informed consent be-
fore enrollment.
Patient assessment
Patient assessment was performed within 2 weeks before
the start of treatment. The items included a complete
medical history, comprehensive physical examination,
thoracic, abdominal and head enhanced computed tomog-
raphy (CT) or head magnetic resonance imaging (MRI),
ECG, bronchoscopy, whole-body bone scanning using
emission CT (ECT) as suggested by clinical, routine blood
tests, and full blood biochemical items.
Patients received a physical examination and routine
blood tests every week (if necessary, the frequency could
be increased). The full blood biochemical tests and ECG
were re-examined before each chemotherapy treatment.
Research design
This phase II clinical trial was an open-label, single-arm,
and safety study. The primary endpoint was the toxicity
of the accelerated hypofractionated three-dimensional
conformal radiation therapy (69 Gy, 3 Gy/fraction) with
concurrent chemotherapy program. The secondary re-
search endpoint included progression-free survival (PFS),
median survival time (MST), OS, and local control (LC).
A sample size of 30 evaluable patients was determined ar-
bitrarily, if the toxicity induced by the regimen could be
tolerated [33].
Radiotherapy
The three-dimensional conformal technology with acceler-
ated hypofractionated radiotherapy was completed within
4.6 weeks, with a total dose of 69 Gy, delivered at 3 Gy per
fraction, once daily, five fractions per week. The chemora-
diotherapy treatment scheme is depicted in Table 1.
The specific radiotherapy program has been described
in detail in the phase I trial [32]. The limitation condi-
tions of irradiation on important organs were as follows:
V20 ≤ 30 %, spinal cord 0 % > 40 Gy, and ≤12 cm esopha-
gus within PTV [24, 27]. Limitation of irradiation to the
esophagus was not mandatory, and could be appropriately
broadened for the better PTV irradiation.
Chemotherapy
Chemotherapy was conducted concurrently with radio-
therapy. Chemotherapy regimen 1 was as follows: vino-
relbine (NVB) was administered by intravenous infusion
at a dose of 25 mg/m2 on day 1 (d1) and day 8 (d8), and
carboplatin (CBP) was administered at a concentration-
time curve (AUC) of 5 mg/ml on d8. This treatment was
repeated every 28 days. One cycle of chemotherapy was
performed concurrently with the radiotherapy. Chemo-
therapy regimen 2 was as follows: paclitaxel at 30 mg/m2
and cisplatin at 20 mg/m2 (TP) were administrated every
week for 5 weeks continuously.
Table 1 Concurrent chemoradiotherapy schema
Concurrent chemoradiotherapy schema
RT regimen: Weeks 1–5: 3 Gy/f, 1 f/d,5 f/w;
Week 1 2 3 4 5
RT ┃┃┃┃┃ ┃┃┃┃┃ ┃┃┃┃┃ ┃┃┃┃┃ ┃┃┃
Chemotherapy for Patient1-6: NVB (25 mg/m2) d1, d8; CBP,AUC = 5 mg/m1.min on d8, repeated every 28 days
NVB ♦ ♦ ♦ ♦
CBP ● ●
Chemotherapy for Patient7-12: Paclitaxel(T): 30 mg/m2,Cisplatin(P) 20 mg/m2,weekly,w1-w5.
TP ▲ ▲ ▲ ▲ ▲
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After radiotherapy was finished, consolidation of che-
motherapy using the original regimen was conducted for
a maximum of four cycles.
Supportive care and dose adjustment
The regimen of supportive care and dose adjustment is
described in detail in the phase I trial [32].
Evaluation of short-term efficacy and toxicity
Four weeks after the completion of radiotherapy, the
short-term efficacy was evaluated using the thoracic-
abdominal spiral CT based on the Response Evaluation
Criteria in Solid Tumors, version 1.1, (RECIST 1.1) stand-
ard [34]. The Common Terminology Criteria for Adverse
Events (CTCAE), version 3.0 issued by the National Can-
cer Institute/National Institutes of Health (NCI/NIH) was
used as the standard for toxicity evaluation [35]. Evalu-
ation was performed each week during the radiotherapy.
Adverse events that occurred more than 90 days after the
beginning of radiotherapy were classified as late toxicity.
Follow-up and statistics
A follow-up was conducted every 2 months for the first
6 months after the completion of radiotherapy, every
3 months between 6 months and 2 years, and every
6 months thereafter. All of the statistical analyses were
performed using the SPSS 19.0 biostatistical software
package or the R3.2.2 statistical software package. The
95 % confidence interval was calculated using the exact
binomial test. Regression analysis was performed using
logistic regression. The correlation analysis of esopha-
gitis was performed using Spearman’s testing [22]. The
survival data were evaluated using the Kaplan-Meier
method. The survival time was measured from the initi-
ation of the concurrent radiochemotherapy until death
due to any cause or the last follow-up event. Only the
first treatment failure was considered as the reason for
failure. PFS was defined as survival without local recur-
rence or distant metastases.
Results
Patient condition
From April 2013 to July 2014, 12 patients with previously
untreated NSCLC confirmed by pathology and cytology
were enrolled in this study; all 12 cases received toxicity
and efficacy evaluations. The clinical information of pa-
tients is shown in Table 2. The median age was 65 years,
and the median KPS score was 80. There were nine cases
of squamous carcinoma, two cases of adenocarcinoma
and one case of undifferentiated carcinoma. There were
four cases with stage IIIA and eight cases with stage IIIB
disease. The details of the clinical staging are shown in
Table 3. The median gross tumor volume (GTV) was
55.7 cm3 (mean, 65.3 cm3; range, 7.9–178.0 cm3), and the
median planning target volume (PTV) was 261.0 cm3
(mean, 263.3 cm3; 130.3–415.7 cm3).
Compliance
Seven among the 12 cases completed the 69-Gy radi-
ation according to the treatment protocol. Five cases did
not complete the protocol due to severe radiation esopha-
gitis, one case suspended the radiotherapy for 16 days
(suspension of radiation for more 14 days was considered
a major violation of the treatment plan), and the other
four cases completed 51 Gy, 51 Gy, 54 Gy, and 66 Gy of
radiation. The 95 % unilateral confidence interval of grade
III and above esophagitis was ≥18.26 %. The incidence of
severe esophagitis (grade III and above) in lung cancer
Table 2 Patient characteristics
Characteristic No. of patients Percentage of











Squamous cell carcinoma 9 75.0
Adenocarcinoma 2 16.7




Table 3 Detailed staging for patients with NSCLC
NO. Location Stage TNM Nodal staging
1 Right upper IIIA T2aN2M0 4R, 4 L, 10
2 Right upper IIIA T3N2M0 2R, 4R,
3 Left lower IIIA T4N0M0 None
4 Left lower IIIB T1bN3M0 4R, 4 L
5 Right upper IIIB T4N3M0 1R, 2R, 4R, 4 L, 5, 7, 8, 10
6 Right upper IIIB T4N3M0 4R, 4 L, 5, 10
7 Right upper IIIB T2aN3M0 4R, 10, supraclavicular
8 Right middle IIIA T3N2M0 1, 2R, 3A, 4R, 6
9 Right lower IIIB T4N2M0 2R, 4R, 5, 7
10 Right upper IIIB T4N3M0 4R, 4 L, 7, 10
11 Right upper IIIB T4N2M0 2R, 4R, 7, 10
12 Right upper IIIB T4N3M0 1R, 2R, 3P, 4R, 5,7
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radiotherapy does not have recognized standards [36], es-
pecially for hypofractionated concurrent radiochemother-
apy [22]. We referenced the mean value, 15 % (6–24 %),
reported in literature, which was used as the standard
[36]. After hypothesis testing, the results showed a signifi-
cant difference (p = 0.02392). Therefore, we consider the
incidence of severe esophagitis in our phase II trial higher
than that in general studies. In addition, severe esophagitis
significantly affected the completion of radiotherapy, and
this radiotherapy regimen was not easy to implement in
clinical practice. Therefore, this trial was terminated early
after only 12 patients were enrolled in the study. All of the
patients who received NC treatment completed 1 cycle of
concurrent chemotherapy. Six patients who received
weekly TP treatment completed 5, 4, 3, 3, 3, and 3 times
of weekly concurrent chemotherapy.
Non-hematological toxicity
The detailed non-hematological toxicities are shown in
Table 4. Five patients had acute grade III radiation
esophagitis; which occurred at 30 Gy/10 fractions (No.
5), 36 Gy/12 fractions (No. 9), 45 Gy/15 fractions (No.
10), 39 Gy/13fractions (No. 11), and 45 Gy/15 fractions
(No. 12). They were all given supportive measures such
as intravenous infusion, antacid, and protection of esopha-
gus and gastric mucosa. Patient No. 5 had severe esopha-
geal pain at 45 Gy/15 fractions; due to the poor effect of
narcotic analgesics, the patient could not tolerate and gave
up the radiotherapy for a total of 16 days; the patient re-
sumed the radiotherapy after esophagitis was reduced to
grade II and finally completed 69 Gy/23 fractions. The
other four patients who had grade II radiation esophagitis
continued for 7–10 days; although they did not interrupt
radiotherapy, they all did not finish the protocol and
finally completed 51 Gy, 54 Gy, 51 Gy, and 66 Gy of radio-
therapy, respectively.
After the radiotherapy was completed, the radiation
esophagitis of patient No. 5, 9, and 11 recovered rapidly,
and significant late-stage reaction was not observed (the
follow-up time was 3, 6, and 5, respectively; at the 3-
month follow-up time, patient No.5 had already died).
Patient No.10 had grade I esophagitis at the completion
of radiotherapy; the patient had complete remission after
the disease was persistent for 2 months and could re-
sume normal eating (the follow-up time was 3 months).
Patient No.12 already had dysphagia before admission
and had semi-liquid food before radiotherapy. Esopha-
geal imaging showed extrinsic compression changes and
local stenosis. After radiotherapy, the dysphagia was par-
tially relieved but was further aggravated after 3 months
of radiotherapy than before radiotherapy. It was evalu-
ated as a late esophageal toxicity of grade II. The disease
was further aggravated after 6 months, and the patient
could only take liquid food. Esophageal dilation therapy
or gastrostomy was required (refused by the patient);
thus, it was evaluated as a late esophageal toxicity of
grade III. However, the disease evaluation showed that
the local control and distant metastasis were relieved
(the follow-time was 9 months).
We attempted to analyze factors associated with severe
radiation esophagitis. Because of the limitations of the
small sample size, only the two most likely associated
factors relevant to clinical practice could be analyzed:
metastasis of the seventh lymph node (mStation 7) and
PTV volume. The results showed that neither mStation
7 nor PTV volume were significantly correlated with
severe esophagitis; the z values were 0.001 and 0.000,
respectively, and the p values were 1.000 and 1.000,
Table 4 Non-hematologic toxicity
Item Grade I Grade II Grade III Grade IV Total
Case % Case % Case % Case % Case %
Acute
Radiation esophagitis 2 16.7 2 16.7 5 41.7 0 0 9 75.0
Radiation pneumonia 2 16.7 1 8.3 2 16.7 0 0 5 41.7
Radiation dermatitis 7 58.3 0 0 0 0 0 0 7 58.3
Nausea 3 25.0 5 41.7 2 16.7 0 0 10 83.3
Vomiting 4 33.3 2 16.7 0 0 0 0 6 50.0
Anorexia 2 16.7 4 33.3 2 16.7 0 0 8 66.7
Fatigue 4 33.3 2 16.7 1 8.3 0 0 7 58.3
ALT/ AST 2 16.7 0 0 0 0 0 0 2 16.7
BIL 3 25.0 1 8.3 0 0 0 0 4 33.3
Late
Lung 2 16.7 2 16.7 1 8.3 0 0 5 41.7
Esophagus 0 0 0 0 1 8.3 0 0 1 8.3
ALT alanine aminotransferase, AST aspartate aminotransferase, BIL bilirubin
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respectively. Nevertheless, we observed that five patients
with grade III radiation esophagitis all showed mStation
7, while the seven patients who did not exhibit grade III
and above esophagitis did not show mStation 7. The
Station 7 is adjacent to the esophagus. Lymph node me-
tastasis in this region is easy to induce with a high dose
of radiation in the esophagus, thus causing severe
esophagitis. Although the regression analysis results did
not show remarkable significance, we still propose that
mStation 7 might be a risk factor for severe esophagitis.
The final conclusion requires confirmation in future
studies using large sample sizes.
Among the seven cases that completed the 69 Gy ac-
cording to the treatment plan, three cases had symptom-
atic pneumonitis (grade II + III); however, among the five
cases for which the protocol was not completed, there was
no pneumonitis. The comparison between these two
showed a significant difference (χ2 = 3.935, P = 0.047).
Nausea, fatigue, and loss of appetite were observed in
most patients. However, these digestive tract symptoms
were mild and were successfully alleviated through the ad-
ministration of appropriate antiemetics and intravenous
rehydration without affecting the implementation of che-
moradiotherapy. Liver and kidney toxicities were rare.
The detailed non-hematological toxicities are shown in
Table 4.
Radiation dose on the esophagus
The detailed information of the radiation of the esopha-
gus is shown in Tables 5, 6 and 7. The mean dose was
from 263 Gy to 4,282 Gy, and the maximum dose was
from 2,832 Gy to 7,222 Gy. The dose volume parameters
are shown in Table 5. The percentage of the esophageal
volume that received a 5 Gy or greater radiation dose
(V5) was set as the starting point. The dose increments
of 5 Gy was used until V69 (the percentage of the esopha-
geal volume that received a 69 Gy or greater radiation
dose); a total of 14 dosimetric-volumetric parameters ran-
ging from V5 to V69 were defined. The irradiation dose
per fraction parameters are shown in Table 6. The
Spearman’s testing results showed that grade III acute
esophagitis had a significant positive correlation with the
irradiation dose per fraction to the esophagus, the total of
14 dose-volume parameters (V5-V69), maximum radi-
ation dose, and mean radiation dose (P < 0.05).
Hematological toxicity
Neutropenia occurred in 58.3 % (7/12) of patients; the
overall disease was milder, and only one case had agran-
ulocytosis (8.3 %). The percentage of the decrease of
platelets and hemoglobin was low, and grade II and
above disease did not occur. The hematological toxicity
of weekly TP treatment was significantly milder than
that in NC chemotherapy; the percentages of neutro-
penia were 16.7 % and 100 %, respectively. The detailed
hematological toxicities are shown in Table 8.
Short-term treatment efficacy
Evaluation of the short-term treatment efficacy was per-
formed on 12 cases. The results showed that the com-
plete response (CR) was 0 % (0/12), the partial response
(PR) was 61.5 % (11/12), and the stable disease (SD) was
Table 5 Irradiation dose to esophagus:a Dose-volume
NO. V5 V10 V15 V20 V25 V30 V35 V40 V45 V50 V55 V60 V65 V69
(%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
1 9.93 1.31 0.52 0 0 0 0 0 0 0 0 0 0 0
2 39.71 29.79 28.22 25.34 18.29 14.63 12.28 11.76 9.93 7.05 3.14 0 0 0
3 31.35 31.35 31.35 31.35 30.31 30.31 30.31 30.31 30.31 30.31 29 25.87 19.60 0.78
4 41.54 38.67 38.67 38.67 24.82 0 0 0 0 0 0 0 0 0
5 65.32 62.97 60.36 58.00 58.00 58.00 57.74 57.22 56.70 55.39 50.95 49.90 41.81 6.01
6 37.10 30.05 27.96 24.56 24.04 23.52 19.33 9.93 3.66 2.87 0 0 0 0
7 30.31 30.31 29.52 19.07 4.96 2.87 2.61 1.57 0 0 0 0 0 0
8 65.06 56.70 53.82 49.38 45.20 33.97 32.66 25.61 4.96 0.52 0 0 0 0
9 44.94 41.54 41.02 40.76 36.58 30.57 20.08 19.33 19.07 18.29 17.51 16.72 15.42 2.35
10 54.09 48.86 45.99 45.46 43.11 42.85 37.89 37.89 34.44 34.23 32.40 28.74 17.24 0
11 40.12 38.93 38.64 36.84 35.80 33.97 32.40 31.62 29.52 28.48 28.22 26.39 26.13 20.12
12 70.02 66.63 65.84 64.54 64.28 64.28 64.01 63.75 61.62 61.40 58.27 53.82 47.03 18.81
p 0.019 0.010 0.019 0.019 0.010 0.002 0.009 0.004 0.004 0.004 0.002 0.000 0.001 0.006
rb 0.661 0.710 0.661 0.661 0.710 0.786 0.711 0.760 0.764 0.764 0.787 0.862 0.810 0.737
aThe cell values demonstrate the percent of total esophagus volume receiving a dose or greater than a certain dose. For example, “V50 = 29 %” demonstrated
that the esophagus volume received 50Gy or more was 29 %
b“r” refers to the correlation coefficient calculated by Spearman’s testing
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8.3 % (1/12). There was no progressive disease (PD), and
the total response rate (RR) was 91.7 % (11/12).
Survival
Although this phase II trial was prematurely terminated,
we still reported the preliminary survival results. Because
the follow-up time was short (5–16 months), the median
follow-up was 10 months, there were only two cases of
death, and the survival information of OS was not mature.
The median PFS, OS and LC, were not reached. The mean
PFS, OS, and LC were 12.3, 14.3, and 12.9 months,
respectively. The 1-year PFS, OS, and LC were 58.3 %,
78.6 %, and 64.2 %, respectively. There were four cases of
treatment failure with two cases of simple local progres-
sion, one case of local progression plus distant metastasis
(metastasis in both lung), and one case of simple distant
metastasis (multiple ipsilateral lung metastasis). Regarding
the cause of the two deaths, one case was due to local pro-
gression, and one case was due to local progression plus
distant metastasis.
Discussion
The treatment failure of the primary lesions of NSCLC
had negative effects on PFS, metastasis-free survival, and
OS [37]. Increasing the tumor radiation dose could in-
crease the local control and improve survival [5, 38]. A
study using model analysis obtained the same conclu-
sion: the radiotherapy dose and survival had a significant
dose-effect relationship, and a high radiotherapy dose
could obtain a better 2-year PFS [8]. However, only in-
creasing the radiotherapy dose alone was not sufficient.
RTOG0617 used 74 Gy for conventional radiotherapy
(concurrent with chemotherapy), and the total treatment
time was as long as 7.4 weeks; the results showed that
OS was not improved [7]. The other key factor for the
radiotherapy efficacy was the total treatment time [10, 11].
Shortening the total treatment time could increase the
BED [11]. Application of the hypofractionated radiother-
apy not only could obtain higher BED but also could
shorten the total treatment time [36]. Therefore, com-
pared with hyperfractionated radiotherapy, it might obtain
more benefits [8].
Table 6 Irradiation dose to esophagus:a Dose per fractionation
NO. 2 Gy 2.2 Gy 2.4 Gy 2.6 Gy 2.7 Gy 2.8 Gy 2.85 Gy 2.9 Gy 2.95 Gy 3 Gy
cm cm cm cm cm cm cm cm cm cm
1 0 0 0 0 0 0 0 0 0 0
2 3 2 0 0 0 0 0 0 0 0
3 8.5 8.5 8.5 7.5 7 6.5 5.5 5 2.5 2
4 0 0 0 0 0 0 0 0 0 0
5 14 14 13.5 13.5 13 12.5 12 10.5 8 4
6 5.5 4.5 4 1 0 0 0 0 0 0
7 2 0 0 0 0 0 0 0 0 0
8 6 5 1.5 0 0 0 0 0 0 0
9 5.5 5.5 4.5 4.5 4.5 4.5 3.5 3 3 2
10 8.5 8.5 8.5 8 7.5 7 6.5 5 0 0
11 7 7 6 6 6 6 6 6 6 6
12 12.5 12.5 12 11 11 11 11 11 7.5 5.5
p 0.018 0.006 0.005 0.002 0.001 0.001 0.000 0.001 0.006 0.009
rb 0.665 0.741 0.749 0.787 0.810 0.810 0.862 0.838 0.737 0.711
aThe cell values demonstrate the whole circumferential length of esophagus receiving a dose greater than a certain dose per fractionation. For example, “2.7Gy =
13 cm” demonstrated that the whole circumferential length of esophagus received 2.7Gy per fraction or more was 13 cm
b“r” refers to the correlation coefficient calculated by Spearman’s testing
Table 7 Irradiation dose to esophagus: Maximum and mean















a“r” refers to the correlation coefficient calculated by Spearman’s testing
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Many studies have reported implementing hypofractio-
nated radiotherapy on unresectable early- and middle-
stage NSCLC (IA-IIB); the results showed that there was
no severe esophagus and lung toxicities, and the survival
results were inspiring [12–15]. Hypofractionated radio-
therapy (with or without sequential chemotherapy) on
locally advanced NSCLC was also safe and effective.
Concerning the toxicity of hypofractionated radiother-
apy, the single fractionated dose was rarely above 3 Gy/
fraction [16–21]. Radiotherapy with 55 Gy/20 fraction
and 2.75 Gy/fraction was extensively applied in the UK.
Din et al. [39] retrospectively analyzed 609 cases of
hypofractionated radiotherapy, and the results showed
that there were 227 cases of IIIA/IIIB, the MST was
20 months, the 2-year OS was 40 %, and toxicity could be
tolerated. This regimen could also be implemented safely
in the elderly population over the age of 80 years [18].
Conventional fractionated radiotherapy with concur-
rent chemotherapy was better than simple radiotherapy
or sequential radiochemotherapy [3, 4]. Theoretically, it
was hypothesized that hypofractionated radiotherapy
with concurrent chemotherapy could reasonably further
increase efficacy. Therefore, studies exploring hypofrac-
tionated radiotherapy with concurrent chemotherapy are
emerging [22–29]. These studies obtained inspiring sur-
vival results: the MST was 13.4–29.5 months, the 1-year
OS was 56–90 %, and the 2-year OS was 30–58.3 %
[24–29]. However, except for two studies [24, 27], all
other studies had a small sample size and were single-
group and phase I/II trials; the number of cases was
small with only 10–37 participants. Therefore, these sur-
vival results must be confirmed by phase III randomized
controlled trials. Although the multivariate analysis in a
non-randomized retrospective study showed that radio-
chemotherapy was the only survival predictive factor
[40], but two prospective studies did not confirm that
concurrent radiochemotherapy was better than sequen-
tial radiochemotherapy [24, 27]. EORTC 08912–22973
was a randomized controlled trial with the most cases; it
enrolled 158 patients and used the radiotherapy regimen
of 66 Gy/24 fractions and 2.75 Gy/fraction. The concurrent
chemotherapy used a low dose of cisplatin at 6 mg/m2
every day. The MST, 2-year OS, and 3-year OS in the con-
current radiochemotherapy group and sequential radioche-
motherapy group were 16.5 months and 16.2 months,
39 % and 34 %, and 34 % and 22 %, respectively; there
were no significant differences [27]. The Sequential or
Concurrent Chemotherapy and Radiotherapy (SOCCAR)
trial enrolled 130 cases. The radiotherapy regimen was
55 Gy/20 fractions and 2.75 Gy/fraction. The chemother-
apy was the vinorelbine + cisplatin regimen. Although
both groups obtained good survival results, there was no
significant difference. The MST, 1-year OS, and 2-year OS
in these two groups were 24.3 months and 18.4 months,
70 % and 83 %, and 50 % and 46 %, respectively [24]. The
hypofractionated regimens used in the above studies had
very large differences; the fractionated dose ranged from
2.4 Gy/fraction to 3.5 Gy/fraction, the total dose ranged
from 52.5 Gy to 66 Gy, and the total treatment time
ranged from 26 days to 37 days, and the results were dif-
ferent; therefore, it was difficult to choose the best regi-
men from these results.
Our previous study performed dose escalation of the 3-
Gy/fraction radiotherapy. The maximum-tolerated dose
(MTD) recommended in the phase II trial was 69 Gy/23
fractions [32]. However, currently, our phase II trial only
enrolled 12 cases. Due to the aggressive esophageal tox-
icity (mainly esophageal pain) and lung toxicity, the trial
was prematurely terminated. The percentage of grade III
acute esophagitis in our study was far higher than those in
other hypofractionated reports and reached 41.7 % (5/12).
Five cases presented with intolerable esophageal pain, and
80 % (4/5) had different degrees of dysphagia, of which
one case had very severe dysphagia and could only drink a
small amount of water. It was considered that the reasons
for the development of such severe esophagitis might be
associated with the following factors. First, the total dose
was 69 Gy, and the fractionated dose was 3 Gy/fraction in
our radiotherapy regimen. The radiation on the esophagus
regardless of the total dose or single dose might both be
very high [41, 42]. In addition, since the single fractionated
dose was large, the rapidity of dose accumulation on the
esophagus might cause severe esophagitis [36]. Second,
the whole group had 41.7 % lymph node metastasis with
more than four stations and 50 % N3 lesions, thus causing
extensive involvement of the mediastinum. Mediastinal in-
filtration and extensive lymph node metastasis are factors
for the high incidence of esophagitis [16]. Third, 41.7 %
patients had Station 7 metastasis. Station 7 was adjacent
to the esophagus; therefore, it was easy to cause the high-
dose radiation on esophagus. In our study, the occurrence
of esophagitis was early; the earliest case (No. 5) had
Table 8 Hematologic toxicity
Item Grade I Grade II Grade III Grade IV Total
Case % Case % Case % Case % Case %
Neutropenia 1 8.3 3 25.0 1 8.3 1 8.3 6 50.0
Thrombocytopenia 3 25.0 0 0 0 0 0 0 3 25.0
Anemia 2 16.7 0 0 0 0 0 0 2 16.7
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already developed the complication at the 10th fraction.
Although the corresponding measures such as narcotic
analgesic drug administration and nutrition support were
provided, the grade III esophagitis persisted for 23 days
before being reduced to grade II, thus causing 16 days of
radiotherapy interruption. This patient had eight stations
of mediastinal lymph node metastasis—1R, 2R, 4R, 4 L, 5,
7, 8, and 10. The V60 reached 49.9 %. The whole circum-
ferential length of esophagus receiving more than 2.7 Gy
and 3 Gy per fraction reached 13 cm and 4 cm, respect-
ively. Regardless of the total radiation dose, irradiation
length, dose-volume percentage, or irradiation dose per
fraction to esophagus, they were all very high.
The dosimetric parameters of the occurrence of radi-
ation esophagitis might be associated with the maximum
radiation dose, irradiation length, and dose-volume pa-
rameters of the esophagus [41–45]. Our study also con-
firmed these results. However, there were also some
conflicting studies considering that these parameters did
not have a clear correlation with esophagitis [46, 47]. The
dosimetric parameters of radiation esophagitis could not
draw a very firm conclusion [36], particularly for hypofrac-
tionated radiotherapy with concurrent chemotherapy [22].
When the five cases of grade III esophagitis occurred in
our study, the completed radiation dose was only 43 %,
52 %, 57 %, 57 %, and 65 % of the plan. In addition, at the
end, they did not complete the radiation of the total dose
(with the exception of the patient who had a 16-day inter-
ruption). Therefore, the maximum radiation dose and
dose-volume parameters of the esophagus in these pa-
tients might not be the most relevant factors to predict se-
vere esophagitis [36]. Studies have shown that severe
esophagitis was closely associated with the rapid accumu-
lation of the radiation dose of the esophagus, a finding
that might be more important than the final completed
total irradiation dose [36]. A single large-dose radiation on
the esophagus would induce the rapid increase of the radi-
ation dose of the esophagus. Our study also observed this
condition: the percentage of severe esophagitis in patients
who received one single dose per fraction of ≥2.7-Gy radi-
ation on the esophagus was markedly higher than in those
who received a dose lower than 2.7 Gy (80 % vs 0, respect-
ively). Although there was no significant difference, it was
considered that the cause might be due to the very small
sample size. Therefore, we considered that the severe acute
radiation esophagitis might be closely associated with the
irradiation dose per fraction to esophagus ≥2.7 Gy.
Other hypofractionated radiotherapy studies also ex-
hibited similar phenomena [26, 27]. Koukourakis et al.
applied the 3.5 Gy/fraction concurrent radiochemother-
apy, although there was a routine 9-day interval, and
also applied the cytoprotective adjuvant amifostine; how-
ever, the grade III esophagitis still reached 22.5 % [26]. A
study that applied 2.75 Gy/fraction had 17 % grade III/IV
esophagitis [27]. In these two high single-dose hypofrac-
tionated studies, the percentages of esophagitis were sig-
nificantly higher than those in hypofractionated studies
using a relatively smaller single dose [25, 28, 29]. EORTC
08912 [23] applied a large fractionated dose of 2.75 Gy/
fraction; 17 cases received a total radiation dose >60 Gy of
the esophagus that was one single irradiation dose of
>2.5 Gy/fraction, and the mean length reached 11.4 cm.
However, there were only two cases of grade III esopha-
gitis; the radiation doses of the esophagus of these two
cases were 65 Gy and 66 Gy, respectively—that is, the sin-
gle irradiation doses were 2.71 Gy and 2.75 Gy, respect-
ively. These results were consistent with our study results
suggesting that the single dose equal to or larger than
2.7 Gy would induce severe esophagitis. Research in the
Netherlands reported two cases of grade IV esophageal
toxicity of which the radiation dose of the esophagus in
one case was 66 Gy/27 fraction and 2.75 Gy/fraction [40].
The above analyses supported the following conclusion. A
single dose radiation per fraction ≥2.7 Gy in hypofractio-
nated radiotherapy with concurrent chemotherapy might
induce severe radiation esophagitis. In the three studies
applying relatively small fractionated doses (2.5 Gy, 2.4 Gy,
and 2.4 Gy, respectively), two studies did not have grade
III or higher esophagitis [25, 29], and the other one only
had 3 % of grade III esophagitis [28]. However, the num-
ber of cases in these studies was small, and the number of
severe esophagitis cases was even smaller; therefore, this
phenomenon was not a confirmed conclusion. In our
study, among the five cases of grade III acute esophagitis,
only one case was finally transformed into late grade III
esophageal injury, indicating that 69 Gy might not cause a
severe late esophageal toxicity. However, this result should
be treated cautiously because only one case among these
five cases completed 69 Gy of radiation (the radiotherapy
was interrupted for 16 days due to esophagitis). This case
showed rapid disease progression and died after 4 months
of completion of the radiotherapy; the observation time
was short and was not sufficient to exclude the possibility
of the occurrence of grade III and above late esophageal
injury. Three of other four cases completed only 74–78 %
of the radiation dose; therefore, it could not verify the
safety of the 69 Gy of radiation.
In our study, two cases of grade III radiation pneu-
monitis (16.7 %) transformed into one case of late grade
III lung injury and one case of late grade II lung injury
after 90 days. It was worth noting that patients who
completed 69 Gy of radiation according to the plan had
28.6 % grade III radiation pneumonitis (2/7), and the ac-
tual incidence of lung injury might be underestimated
(one case died due to disease progression after 4 months
of the completion of radiotherapy; thus, the evaluation
time for lung injury was short). Currently, there are no
established data to guide the prevention and reduction
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of the development of radiation pneumonia during hypo-
fractionated radiotherapy. Studies have shown that appli-
cation of hypofractionated radiotherapy using the dose
parameters obtained mainly from conventional hypofrac-
tionated radiotherapy might induce severe lung toxicity
[48, 49]. Therefore, the possibility of developing severe ra-
diation pneumonia during hypofractionated radiotherapy
is highly vigilant.
In our study, at the median 10-month follow-up, as
high as 41.7 % grade III acute esophagitis and 28.6 %
grade III acute pneumonitis (patients who completed the
radiotherapy plan) were already observed. The late lung
toxicity might be underestimated because of short
follow-up time [48]. Because a late lung toxicity was
usually fatal [48, 49], we considered that this hypofrac-
tionated radiochemotherapy regimen was not safe. In
addition, grade III esophagitis in this study presented
prominently esophageal pain; thus, 33.3 % patients in
this group could not complete the whole 69-Gy radio-
therapy, and the compliance of this regimen was poor.
Therefore, this phase II trial was terminated early.
In our phase I study, the 69-Gy group enrolled six pa-
tients. There were only two cases of grade II esophagitis,
and there was no grade III and above esophagitis. The
esophageal toxicity was significantly lower than that in
the current study [32]. We reviewed the dosimetric pa-
rameters of the six patients and found that the max-
imum total doses of the esophagus of all patients were
all ≤55.2 Gy—that is, the maximum single dose per frac-
tion of radiation was ≤2.4 Gy. In the phase II study, the
maximum irradiation dose per fraction to esophagus of
four patients was ≤2.4 Gy, and there was no grade III
esophagitis, findings that were consistent with the result
of the hypofractionated concurrent radiochemotherapy
using a relatively small single dose [25, 28, 29]. In our
phase I study, the 69-Gy group did not have grade III ra-
diation pneumonitis. The latter finding was considered
to be associated with the selection bias caused by the
small number of cases. A similar phenomenon was also
observed in a Canadian report. The maximum single
dose per fraction of the dose-escalation was 3.24 Gy/
fraction, the total dose was 70.7 Gy, the concurrent full-
dose etoposide/cisplatin (EP) chemotherapy regimen was
conducted for 2 cycles, and the median 22-month
follow-up showed no grade III and above toxicity. Be-
cause there were only 10 patients in the group, the au-
thors considered that the results should be cautiously
treated with optimism because of the small sample size
[25]. Therefore, if the case number in the dose-escalation
group was small, the result was not sufficient to exhibit
the safety of this dose level, particularly with high-dose
hypofractionated radiation [48]. The survival data in our
study are still not mature, and the MST was not achieved;
however, for the 1-year OS of 78.6 %, these results were
comparable to those of other literature reports (OS from
56 % to 90 %) [24–29].
The studies on conventional fractionated radiotherapy
in NSCLC focused heavily on lung toxicity However, they
did not focus on the protection of the esophagus, and
some studies did not even have limitation of irradiation
dose to esophagus [28, 29, 50]. Currently, the predictive
factors and dose-volume parameters for esophagitis still
cannot provide a confirmed conclusion, and the hypofrac-
tionated radiotherapy even requires new dosimetric pa-
rameters and other factors for evaluation [36]. Although
esophagitis, particularly acute esophagitis, is not fatal, it
might affect the completion of the radiotherapy plan,
interrupt radiotherapy, or decrease the radiation dose,
thus reducing the local control rate. This situation is even
more prominent in hypofractionated radiotherapy. Some
studies have considered that the major obstacle of dose-
escalation in hypofractionated radiotherapy was caused by
the esophagus [37, 40, 48], a finding that was also
confirmed in our phase II study. Therefore, during
hypofractionated radiotherapy, particularly concurrent ra-
diochemotherapy, in addition to lung toxicity, acute
esophageal toxicity should also be given close attention.
The toxicity analysis in hypofractionated concurrent ra-
diochemotherapy showed that the traditional dosimetric
parameters did not have a good correlation with esopha-
gitis [22]. Therefore, exploring new predictive factors for
esophagitis, particularly for late esophageal injury, has very
important clinical significance.
Most radiotherapy studies used the unified prescrip-
tion dose. However, the application of a fixed dose to all
patients might have two consequences. First, some pa-
tients might receive a very low radiotherapy dose with
insufficient treatment intensity, while other patients
might receive a very high radiotherapy dose with strong
side effects. The so-called “in silico” dose prescription
refers to the radiation dose limitation of normal tissues
being set up in advance and is used as a standard to
allow each patient to receive individualized different
maximum radiation doses without increasing toxicity;
thus, the treatment intensity is sufficient and safe; this
dose is also called the “isotoxic” prescription dose
[37, 50–52]. In hyperfractionated studies, the application
of this method effectively allows escalation of the radio-
therapy dose; in addition, the mature survival results
showed that the MST at the IIIB phase reached
17.2 months. This series of studies only conducted
limitations of radiation dose on the lung and spinal
cord [50–52]. Hoffmann et al. [37] applied the in silico
method to perform a study on individualized dose pre-
scription for hypofractionation and pre-set the limits of
radiation dose on the esophagus, lung, spinal cord, heart,
and brachial plexus. The results of the model analysis
showed that 79 % of cases had a therapeutic gain in dose
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escalation. During the pre-set of the radiation dose for
normal tissues, the “physical dose” was transformed into
the “biological effective dose”; thus, it was more in line
with the radiation injury reaction of normal tissues
after radiation and might be beneficial for reducing
toxicity [16, 25].
Modern advance radiotherapy technologies, including
intensity-modulated radiation therapy (IMRT), image-
guided radiation therapy (IGRT), 4D-CT, breathing
adapted radiotherapy, particle radiotherapy [53], and
tomotherapy [54], can more accurately irradiate tumors;
at the same time, the radiation dose of surrounding nor-
mal tissues can be reduced. Using the in silico method
combined with advanced radiotherapy technology to
perform radiotherapy with an individualized maximum
dose based on the isotoxicity of normal tissues can the-
oretically achieve the dose-escalated hypofractionated
concurrent radiochemotherapy more safely.
Conclusion
In summary, although our hypofractionated concurrent
chemoradiotherapy regimen (69 Gy/23 fractions, 3 Gy/
fraction) showed preliminary efficacy, it resulted in ag-
gressive esophagus and lung toxicity; particularly, severe
esophagitis significantly affected the completion of radio-
therapy. Therefore, this regimen was not feasible. Al-
though, it was not the final conclusion, our study
suggested that an irradiation dose per fraction to esopha-
gus during hypofractionated concurrent radiochemother-
apy should be controlled to be below 2.7 Gy. Currently,
we are performing radiation dose escalation in hypofrac-
tionated radiochemotherapy of NSCLC using the in silico
method according to different irradiation doses per frac-
tion to the esophagus.
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